HRP20040261A2 - Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline - Google Patents

Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline Download PDF

Info

Publication number: HRP20040261A2
Authority: HR; Croatia
Prior art keywords: tetrahydroisoquinol; methanesulfonamido; dimethoxy; pyridyl; quinazoline
Prior art date: 2001-10-11

Application number

HR20040261A

Other languages

English (en)

Croatian (hr)

Inventor

John Douglas Davis

Michael John Humphrey

Ross James Macrae

Janet Sarah Smith

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-11

Filing date

2004-03-17

Publication date

2004-08-31

2004-03-17 Application filed by Pfizer filed Critical Pfizer

2004-08-31 Publication of HRP20040261A2 publication Critical patent/HRP20040261A2/hr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

HR20040261A 2001-10-11 2004-03-17 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline HRP20040261A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0124455.7A GB0124455D0 (en)	2001-10-11	2001-10-11	Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (fr)	2001-10-11	2002-09-30	Formulations pharmaceutiques destinees a la liberation controlee de 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number	Publication Date
HRP20040261A2 true HRP20040261A2 (en)	2004-08-31

Family

ID=9923660

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20040261A HRP20040261A2 (en)	2001-10-11	2004-03-17	Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline

Country Status (32)

Country	Link
EP (1)	EP1434570B8 (fr)
JP (1)	JP4131471B2 (fr)
KR (1)	KR20050032510A (fr)
CN (1)	CN1568180A (fr)
AP (1)	AP2004003001A0 (fr)
AR (1)	AR036782A1 (fr)
AT (1)	ATE303135T1 (fr)
BR (1)	BR0213196A (fr)
CA (1)	CA2461168A1 (fr)
CO (1)	CO5560534A2 (fr)
DE (1)	DE60205925T2 (fr)
DK (1)	DK1434570T3 (fr)
DO (1)	DOP2002000464A (fr)
EA (1)	EA006168B1 (fr)
ES (1)	ES2246017T3 (fr)
GB (1)	GB0124455D0 (fr)
GT (1)	GT200200184A (fr)
HR (1)	HRP20040261A2 (fr)
HU (1)	HUP0600064A3 (fr)
IL (1)	IL160969A0 (fr)
IS (1)	IS7179A (fr)
MA (1)	MA27075A1 (fr)
MX (1)	MXPA04003293A (fr)
NO (1)	NO20041520L (fr)
OA (1)	OA12709A (fr)
PA (1)	PA8556001A1 (fr)
PE (1)	PE20030551A1 (fr)
PL (1)	PL369666A1 (fr)
SV (1)	SV2004001279A (fr)
UY (1)	UY27477A1 (fr)
WO (1)	WO2003032956A1 (fr)
ZA (1)	ZA200401976B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0317663D0 (en) *	2003-07-29	2003-09-03	Astrazeneca Ab	Pharmaceutical composition
AP2015008789A0 (en)	2013-03-14	2015-10-31	Cytokinetics Inc	Heterocyclic compounds and their uses
KR101943592B1 (ko)	2017-08-31	2019-01-30	조현우	데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0466986B1 (fr) *	1990-07-02	1994-04-27	Bend Research, Inc.	Perles asymétriques et microporeuses à libération contrôlée
FR2752737B1 (fr) *	1996-08-29	1998-10-02	Synthelabo	Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) *	1997-01-11	1997-02-26	Pfizer Ltd	Pharmaceutical compounds
IL141235A (en) *	2000-02-09	2012-04-30	Novartis Int Pharm Ltd	Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
GEP20043364B (en) *	2000-03-03	2004-03-10	Pfizer	4-Amino-6,7-Dimethoxy-2-(5-Methanesulfonamido-1,2,3,4- Tetrahydroisoquinol-2-Yl)-5-(2-Pyridyl) Quinazoline Mesylat And Polymorphs

2001
- 2001-10-11 GB GBGB0124455.7A patent/GB0124455D0/en not_active Ceased
2002
- 2002-09-12 DO DO2002000464A patent/DOP2002000464A/es unknown
- 2002-09-17 GT GT200200184A patent/GT200200184A/es unknown
- 2002-09-30 HU HU0600064A patent/HUP0600064A3/hu unknown
- 2002-09-30 JP JP2003535760A patent/JP4131471B2/ja not_active Expired - Fee Related
- 2002-09-30 AT AT02775048T patent/ATE303135T1/de not_active IP Right Cessation
- 2002-09-30 CA CA002461168A patent/CA2461168A1/fr not_active Abandoned
- 2002-09-30 OA OA1200400094A patent/OA12709A/en unknown
- 2002-09-30 EA EA200400431A patent/EA006168B1/ru not_active IP Right Cessation
- 2002-09-30 AP APAP/P/2004/003001A patent/AP2004003001A0/en unknown
- 2002-09-30 CN CNA02820042XA patent/CN1568180A/zh active Pending
- 2002-09-30 KR KR1020047005316A patent/KR20050032510A/ko not_active Application Discontinuation
- 2002-09-30 PL PL02369666A patent/PL369666A1/xx not_active Application Discontinuation
- 2002-09-30 BR BR0213196-0A patent/BR0213196A/pt not_active IP Right Cessation
- 2002-09-30 WO PCT/IB2002/004040 patent/WO2003032956A1/fr active IP Right Grant
- 2002-09-30 ES ES02775048T patent/ES2246017T3/es not_active Expired - Lifetime
- 2002-09-30 DE DE60205925T patent/DE60205925T2/de not_active Expired - Lifetime
- 2002-09-30 DK DK02775048T patent/DK1434570T3/da active
- 2002-09-30 EP EP02775048A patent/EP1434570B8/fr not_active Expired - Lifetime
- 2002-09-30 MX MXPA04003293A patent/MXPA04003293A/es active IP Right Grant
- 2002-09-30 IL IL16096902A patent/IL160969A0/xx unknown
- 2002-10-09 UY UY27477A patent/UY27477A1/es not_active Application Discontinuation
- 2002-10-09 AR ARP020103805A patent/AR036782A1/es unknown
- 2002-10-09 PE PE2002000996A patent/PE20030551A1/es not_active Application Discontinuation
- 2002-10-10 SV SV2002001279A patent/SV2004001279A/es not_active Application Discontinuation
- 2002-10-10 PA PA20028556001A patent/PA8556001A1/es unknown
2004
- 2004-03-11 IS IS7179A patent/IS7179A/is unknown
- 2004-03-11 ZA ZA200401976A patent/ZA200401976B/en unknown
- 2004-03-17 HR HR20040261A patent/HRP20040261A2/hr not_active Application Discontinuation
- 2004-03-18 CO CO04025929A patent/CO5560534A2/es not_active Application Discontinuation
- 2004-04-05 NO NO20041520A patent/NO20041520L/no unknown
- 2004-04-08 MA MA27623A patent/MA27075A1/fr unknown

Also Published As

Publication number	Publication date
EA006168B1 (ru)	2005-10-27
DE60205925D1 (de)	2005-10-06
OA12709A (en)	2006-06-26
HUP0600064A2 (en)	2006-06-28
ATE303135T1 (de)	2005-09-15
EP1434570B1 (fr)	2005-08-31
DOP2002000464A (es)	2003-04-15
CA2461168A1 (fr)	2003-04-24
UY27477A1 (es)	2003-05-30
JP2005507909A (ja)	2005-03-24
CO5560534A2 (es)	2005-09-30
EP1434570A1 (fr)	2004-07-07
GB0124455D0 (en)	2001-12-05
HUP0600064A3 (en)	2007-02-28
SV2004001279A (es)	2004-02-19
ES2246017T3 (es)	2006-02-01
IS7179A (is)	2004-03-11
MA27075A1 (fr)	2004-12-20
PA8556001A1 (es)	2003-07-28
BR0213196A (pt)	2004-08-31
PL369666A1 (en)	2005-05-02
IL160969A0 (en)	2004-08-31
AR036782A1 (es)	2004-10-06
JP4131471B2 (ja)	2008-08-13
KR20050032510A (ko)	2005-04-07
NO20041520L (no)	2004-04-05
DE60205925T2 (de)	2006-06-08
AP2004003001A0 (en)	2004-03-31
PE20030551A1 (es)	2003-06-26
CN1568180A (zh)	2005-01-19
EP1434570B8 (fr)	2005-10-26
EA200400431A1 (ru)	2004-08-26
ZA200401976B (en)	2004-07-12
DK1434570T3 (da)	2005-11-07
GT200200184A (es)	2003-05-23
WO2003032956A1 (fr)	2003-04-24
MXPA04003293A (es)	2004-07-23

Publication	Publication Date	Title
US11452689B2 (en)	2022-09-27	Taste-masked pharmaceutical compositions
US10471017B2 (en)	2019-11-12	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
RU2428176C2 (ru)	2011-09-10	Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
CN100402021C (zh)	2008-07-16	包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
AU2005307052B2 (en)	2012-01-12	Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
RU2325163C2 (ru)	2008-05-27	Композиции с пролонгированным высвобождением, включающие ламотригин
US7163696B2 (en)	2007-01-16	Pharmaceutical formulations
WO2009114773A2 (fr)	2009-09-17	Formulations à libération modifiée des médicaments anti-irritabilité
US20100047343A1 (en)	2010-02-25	Multiparticulate formulation having tramadol in immediate and controlled release form
KR20080037680A (ko)	2008-04-30	1-(4-클로로아닐리노)-4-(4-피리딜메틸)프탈라진 및 ｐｈ조절제를 포함하는 고체 제약학적 조성물
US20030039699A1 (en)	2003-02-27	Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
EP1589950A1 (fr)	2005-11-02	Procede pour la fabrication de formes posologiques de produits pharmaceutiques contenant des composants agissant comme un rembourrage protecteur
US20070082051A1 (en)	2007-04-12	Modified Release Formulations of Antihypertensive Drugs
WO2001080824A2 (fr)	2001-11-01	Formes de dosage a liberation a modifiee a double mecanisme pour medicaments faiblement doses
HRP20040261A2 (en)	2004-08-31	Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline
JP2004339072A (ja)	2004-12-02	優れた安定性を有するプラバスタチンナトリウム固形製剤
AU2002341260A1 (en)	2003-04-28	Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
MXPA01002821A (en)	2001-12-04	Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

Legal Events

Date	Code	Title	Description
2004-08-31	A1OB	Publication of a patent application
2005-03-08	OBST	Application withdrawn